Australia Markets open in 1 hr 25 mins

Westpac is now running scared of a class action lawsuit

Tom Richardson
Westpac

Westpac Banking Corp (ASX: WBC) this morning announced that shareholders who elected to participate in its share purchase plan (SPP) can withdraw their applications. 

On November 4 Westpac asked investors to tip in another $2.5 billion into the business.

The plan was to issue $2 billion worth of shares to institutional investors at what was then at a 6.5% discount to the last November 1 closing price of $27.08.

Retail investors were also invited to apply for $500 million worth of shares at the $25.32 price provided to institutions. Or the volume weighted average price (“VWAP”) of Westpac shares traded on the ASX during the five trading days up to December 2 less a 2 per cent discount. 

Given Westpac shares last closed at $24.81 it appears retail investors will be offered the shares cheaper than $25.32. Notably, this will not Westpac’s powerful institutional backers. 

Of course the SPP was announced prior to the shock November 20 announcement that Westpac was subject to a major regulatory investigation by AUSTRAC.

The AML regulator’s claims against Westpac are so serious that both the CEO and chairman have announced they will leave the bank partly under pressure from powerful institutional investors. 

The bank is probably giving retail investors the option to withdraw or reverse their participation in the SPP as it’s now open to a massive class action alleging it misled the market in not disclosing the AUSTRAC issues at the time of the SPP. 

As such if it offers investors the option to abandon the SPP any potential class action has less members.

Westpac agreed the move “following discussions with ASIC”. 

Worryingly for Westpac shareholders ASIC is reportedly already looking into whether Westpac should have disclosed the AUSTRAC issues at the time of the SPP.

The bank is an an atrocious mess that could get worse if institutional or retail shareholders seek compensation from it over the potential disclosure failures. 

The post Westpac is now running scared of a class action lawsuit appeared first on Motley Fool Australia.

Our Top 3 Blue Chip Shares for 2019 – NOW AVAILABLE!

You’re invited! For a limited time, The Motley Fool Australia is giving away an urgent new investment report detailing our 3 TOP BLUE CHIP SHARES to own in 2019.

So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!

Stock #1 is a beloved old Australian company turning its attention to high-margin businesses... and rapidly returning cash to shareholders with its hefty dividend...

While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe... poised for years (or even decades) of tremendous growth...

Even better, Stock #3 offers a whopping 6.5% grossed-up dividend! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.

You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!

Simply CLICK HERE FOR YOUR FREE REPORT!

More reading

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019